curasan AG receives license for Osbone
11-Dec-2009
- Germany
Hans Dieter Rössler, CEO of curasan AG, explains the advantage of the new product: “Just like the absorbable Cerasorb®, which has already been launched, Osbone® is 100% synthetic and offers practitioners as well as patients the guarantee that the material itself will not result in any adverse effects.“
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.